Loading organizations...
Based in Amsterdam, Netherlands, Delphyr develops AI agents for healthcare professionals to reduce administrative workloads by consolidating patient data from notes, lab results, and correspondence into a single searchable interface. The platform enables quick access to clinical guidelines, generates patient summaries, and supports ambient listening for automatic note creation without requiring new software installations. Regulated as a medical device, the system targets clinicians in hospitals, primary care, and mental health settings while processing data on secure European infrastructure compliant with the EU AI Act, GDPR, ISO 27001, and SOC2. To expand platform deployment and specialized workflows, the startup has raised €1.75 million in early-stage venture funding alongside a €275,000 convertible loan from Innovatiefonds Noord-Holland, securing backing from the founders of Hugging Face and DEGIRO. Delphyr was founded in 2023 by chief executive officer Michel Abdel Malek.
Delphyr has raised $290K across 1 funding round.
Delphyr has raised $290K in total across 1 funding round.
Delphyr has raised $290K across 1 funding round. Most recently, it raised $290K Seed in December 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2024 | $290K Seed | — | Graduate Entrepreneur | Announced |
Delphyr has raised $290K in total across 1 funding round.
Delphyr's investors include Graduate Entrepreneur.
Delphyr is a European health‑tech startup building an AI “Clinical Co‑Pilot” that automates clinical documentation, accelerates retrieval of patient data across EHRs, and supports clinicians’ decision‑making to reduce administrative burden and improve patient outcomes[3][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick final note: Delphyr positions itself as a clinician‑founded, Europe‑based Clinical Co‑Pilot focused on reducing clinicians’ administrative burden through model‑controlled, privacy‑centric AI and is currently moving from early product/validation toward broader hospital trials and deployment[3][2].[3][2]